Want to see HK:6667 full AI Analyst Report?
Top Page
Mega Genomics Limited
(6667)
Select Model
Select Model
Rating:54Neutral
Price Target:
HK$7.00
▼(-3.85% Downside)
Action:N/A
Date:09/22/26
The score is primarily supported by a strong, low-leverage balance sheet, but is held back by weak latest-year cash flow (negative operating and free cash flow) and reduced profitability versus earlier peak years. Technicals are mildly weak with negative MACD and price slightly below major moving averages, while valuation is a further headwind due to a high P/E despite a moderate dividend yield.
Positive Factors
Conservative balance sheet
Very low leverage and a substantial equity base provide financial resilience and flexibility. This structure can help the company withstand operating volatility, fund initiatives without excessive borrowing, and preserve strategic options over the next several quarters.
Negative Factors
Negative latest-year cash flow
Negative operating and free cash flow despite accounting profit signals weak recent cash conversion. Persistent outflows could reduce internally available funding, increase reliance on the strong balance sheet, and constrain investment or shareholder-return capacity.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative balance sheet
Very low leverage and a substantial equity base provide financial resilience and flexibility. This structure can help the company withstand operating volatility, fund initiatives without excessive borrowing, and preserve strategic options over the next several quarters.
Read all positive factors
Mega Genomics Limited (6667) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$1.56B
Dividend Yield2.44%
Average Volume (3M)46.47K
Price to Earnings (P/E)50.1
Beta (1Y)0.06
Revenue Growth169.02%
EPS Growth-24.61%
CountryHK
Employees196
SectorHealthcare
Sector Strength45
IndustryMedical - Care Facilities
Share Statistics
EPS (TTM)0.12
Shares Outstanding224,300,200
10 Day Avg. Volume113,880
30 Day Avg. Volume46,473
Financial Highlights & Ratios
PEG Ratio-1.22
Price to Book (P/B)2.09
Price to Sales (P/S)5.17
P/FCF Ratio-76.55
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Mega Genomics Limited Business Overview & Revenue Model
Company Description
Mega Genomics Limited, a genetic testing platform company, offers consumer genetic testing and cancer screening services in China. It offers brain health assessment package, a service that assesses the risk of various related diseases, including A...
Mega Genomics Limited Financial Statement Overview
Summary
Income Statement
66
Positive
Balance Sheet
84
Very Positive
Cash Flow
45
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2025 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 355.81M | 247.15M | 164.23M | 151.30M | 145.73M | 237.19M |
| Gross Profit | 120.01M | 117.36M | 119.35M | 88.30M | 81.72M | 166.68M |
| EBITDA | 43.31M | 49.68M | 70.03M | 52.42M | -5.42M | 116.67M |
| Net Income | 24.54M | 27.02M | 45.05M | 30.04M | -17.62M | 79.02M |
Balance Sheet | ||||||
| Total Assets | 829.81M | 832.40M | 738.48M | 796.54M | 705.70M | 772.18M |
| Cash, Cash Equivalents and Short-Term Investments | 424.49M | 435.70M | 490.26M | 518.29M | 399.83M | 239.10M |
| Total Debt | 28.52M | 29.37M | 34.40M | 48.56M | 10.99M | 11.57M |
| Total Liabilities | 224.37M | 221.46M | 123.80M | 151.72M | 87.70M | 77.69M |
| Stockholders Equity | 605.44M | 610.94M | 614.68M | 644.83M | 618.00M | 694.50M |
Cash Flow | ||||||
| Free Cash Flow | -15.39M | -16.68M | 56.38M | 127.59M | -12.10M | 26.21M |
| Operating Cash Flow | -15.33M | -16.52M | 57.15M | 163.68M | -6.91M | 30.63M |
| Investing Cash Flow | -18.85M | -16.88M | 6.63M | -33.75M | -2.56M | -1.71M |
| Financing Cash Flow | -9.51M | -41.27M | -91.85M | -12.91M | 158.46M | 2.62M |
Mega Genomics Limited Technical Analysis
Negative
7.28
Price Trends
7.08
Negative
7.01
Negative
7.01
Negative
Market Momentum
-0.03
Positive
46.87
Neutral
76.19
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:6667, the sentiment is Negative. The current price of 7.28 is above the 20-day moving average (MA) of 7.05, above the 50-day MA of 7.08, and above the 200-day MA of 7.01, indicating a bearish trend. The MACD of -0.03 indicates Positive momentum. The RSI at 46.87 is Neutral, neither overbought nor oversold. The STOCH value of 76.19 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:6667.
Mega Genomics Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
82 Outperform | HK$573.95B | 21.48 | 27.24% | 1.14% | 29.92% | 65.54% | |
63 Neutral | HK$1.92B | -32.78 | -3.50% | ― | 9.36% | -153.54% | |
54 Neutral | HK$1.56B | 50.07 | 4.04% | 2.44% | 169.02% | -24.61% | |
52 Neutral | HK$989.26M | -19.87 | -1.56% | 10.00% | 7.95% | 60.86% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
42 Neutral | HK$729.67M | -8.26 | -2.60% | 17.10% | -2.55% | -145.60% |
* Healthcare Sector Average
HK:6667
Mega Genomics Limited
6.96
-0.07
-0.95%
HK:6669
Acotec Scientific Holdings Limited
6.13
-6.48
-51.39%
HK:9960
Kindstar Globalgene Technology, Inc.
0.95
-0.40
-29.42%
HK:1931
IVD Medical Holding Limited
0.45
-8.77
-95.12%
HK:2359
WuXi AppTec Co., Ltd. Class H
209.60
101.54
93.97%
HK:2566
Hangzhou Jiuyuan Gene Engineering Co Ltd Class H
5.70
-6.08
-51.64%
Mega Genomics Limited Corporate Events
Mega Genomics Accelerates Revenue Growth as Product Mix Shift Pressures Profit
Aug 31, 2026
Mega Genomics reported strong top-line momentum for the six months ended 30 June 2026, with operating revenue rising 136.8% year-on-year to RMB192.5 million on the back of expanded product categories and an optimized product structure. The interim...
Mega Genomics Sets Board Meeting to Approve Interim Results and Consider Dividend
Aug 3, 2026
Mega Genomics Limited has scheduled a board meeting for 31 August 2026 to review and approve the group’s interim results for the six months ended 30 June 2026. The board will also consider the declaration of an interim dividend and address a...
Mega Genomics Revamps Hong Kong Governance Roles and Relocates Principal Office
Jul 27, 2026
Mega Genomics Limited has announced changes to its key corporate governance roles in Hong Kong, including the appointment of a new company secretary, authorised representative and process agent. These positions are central to the company’s c...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.